Craft

Capricor Therapeutics

Stock Price

$2.9

2023-11-03

Market Capitalization

$74 M

2023-11-03

Revenue

$2.6 M

FY, 2022

Capricor Therapeutics Summary

Company Summary

Overview
Capricor Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics for the treatment of diseases. Its lead programs target post myocardial infarction (heart attack), heart failure and Duchenne Muscular Dystrophy. As a developer of innovative therapies, Capricor Therapeutics is strategically positioned at the forefront of one of the largest segments of the U.S. healthcare industry − cardiovascular disease.
Type
Public
Status
Active
Founded
2005
HQ
Beverly Hills, CA, US | view all locations
Website
http://capricor.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Linda Marbán

    Linda Marbán, Chief Executive Officer and Director

  • Karen Krasney

    Karen Krasney, Executive Vice President and General Counsel

  • AJ Bergmann

    AJ Bergmann, Chief Financial Officer

  • Kristi A H Elliott

    Kristi A H Elliott, Chief Science Officer

    LocationsView all

    1 location detected

    • Beverly Hills, CA HQ

      United States

      8840 Wilshire Blvd

    Capricor Therapeutics Financials

    Summary Financials

    Revenue (Q2, 2023)
    $3.9M
    Net income (Q2, 2023)
    ($7.4M)
    Cash (Q3, 2023)
    $9.0M
    EBIT (Q2, 2023)
    ($7.7M)
    Enterprise value
    $68.2M

    Footer menu